Analysis on response to darbepoetin alfa in patients with low risk myelodysplastic syndromes

Not Applicable

• Conditions: Myelodysplastic syndromes

• Registration Number: JPRN-UMIN000022185
• Lead Sponsor: Cooperative study between the West Japan Hematology Study Group and Clinical Research Support Center Kyushu

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-05-09
• Study Completion: 2020-08-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 85

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients at risk of thromboembolism with present or past medical history of myocardial infarction, pulmonary infarction and cerebral infarction or similar disorders. 2) Patients with uncontrollable hypertension. 3) Patients with medical history of drug hypersensitivity to darbepoetin alfa or other erythropoietin formulation. 4) Patients with severe (need for hospital care, or judgement by investigators) or uncontrollable complication. 5) Patients inappropriate for study participation due to complication of mental disease or psychiatric symptom. 6) Patients with cognitive disorder. 7) Patients judged by investigators to be inappropriate for study participation.

Study & Design

• Study Type: Interventional
• Study Design: Not specified